Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)

1. Schneeweiss, A.
2. Chia, S.
3. Hickish, T.
4. Harvey, V.
5. Eniu, A.
6. Hegg, R.
7. Tausch, C.
8. Seo, J.H.
9. Tsai, Y.-F.
10. Ratnayake, J.
11. McNally, V.
12. Ross, G.
13. Cortés, J.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDT182 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus